SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2004 VAXGEN, INC. (Exact name of Registrant as Specified in its Charter) DELAWARE 0-26483 94-3236309 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification Number) 1000 MARINA BLVD., SUITE 200, BRISBANE, CALIFORNIA 94005 (Address of Principal Administrative Offices) Registrant's Telephone Number, Including Area Code: (650) 624-1000 Item 5. Other Events and Regulation FD Disclosure. On May 20, 2004, VaxGen, Inc. issued a press release entitled, "VaxGen Receives Notice from Nasdaq Regarding Failure to File Quarterly Report on Form 10-Q". This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (a) Financial Statements. Not applicable (b) Financial Information. Not applicable (c) Exhibits. Exhibit No. Description - ----------- ----------- 99.1 Press release dated May 20, 2004, entitled, "VaxGen Receives Notice from Nasdaq Regarding Failure to File Quarterly Report on Form 10-Q". SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VaxGen, Inc. (Registrant) Dated: May 20, 2004 By: /s/ Lance K. Gordon ------------------------------ Lance K. Gordon President & Chief Executive Officer